US Supreme Court Seems Poised To Allow Patent Holders More Judicial Review Options
Executive Summary
In case that could impact challenges of biopharma patents, Supreme Court questioned the consequences of not allowing courts to review PTAB institution decisions when petition may be time barred.
You may also be interested in...
Mylan's Lantus Rival Faces Fresh Attack
Sanofi seeks to delay decision clearing path for Mylan's Lantus biosimilar; says it should be able to get rehearing based on Federal Circuit's ruling that PTAB judges were not constitutionally appointed.
Sanofi Tries To Stop Lantus Biosimilar By Getting Supreme Court To Review PTAB, Again
Sanofi seeks to delay decision clearing path for Mylan's Lantus biosimilar; says it should be able to get rehearing based on Federal Circuit's ruling that PTAB judges were not constitutionally appointed.
Patent Owners Have One Less Adversary As Supreme Court Bars Government From Filing IPR Petitions
In 6-3 decision, court holds government is not a "person" capable of instituting patent challenges under America Invents Act proceedings.